The company buys Belgium’s EsoBiotec for $425m.
ApexOnco Front Page
Recent articles
The acquisition of Araris follows a 2023 discovery collaboration.
BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
What similarly acting projects are still unpartnered?
After a conference lacking the wow factor, biotech winners and losers emerge.
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.